NSCLC: Moving Second-Line Therapies to Frontline Setting
Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.
Clinical Implications of Real-World Amivantamab Data in NSCLC
Lung cancer experts discuss how these real-world data comparing amivantamab with alternative therapies may impact their clinical practice.
Overview of Real-World Comparative Data for Amivantamab in NSCLC
Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss real-world data comparing amivantamab with other therapies in EGFR exon 20–mutated non–small cell lung cancer.
Real-World Analysis of Amivantamab vs Other Therapies in Exon 20–Mutated NSCLC: Methods
A comprehensive overview of the methods utilized in a real-world analysis of amivantamab vs other therapies in patients with EGFR exon 20–mutated NSCLC.
CHRYSALIS: Amivantamab in Patients with Advanced NSCLC
Expert oncologists review the CHRYSALIS trial, which resulted in the approval of amivantamab in the second line for patients with locally advanced or metastatic NSCLC with exon 20 mutations.
Treatment Options for Patients with EGFR Exon 20–Mutated NSCLC
Experts on non–small cell lung cancer discuss treatment options for patients with EGFR exon 20 mutations in the first line and beyond.
Overview of EGFR Exon 20 Mutations
Joshua K. Sabari, MD, and Helena A. Yu, MD, experts on non–small cell lung cancer, give an overview of EGFR exon 20 insertion mutations.
2 Clarke Drive Cranbury, NJ 08512